A detailed history of Jacobs & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Jacobs & CO holds 61,196 shares of ABBV stock, worth $10.5 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares
61,196
Previous 62,933 2.76%
Holding current value
$10.5 Million
Previous $9.75 Million 14.26%
% of portfolio
1.18%
Previous 1.11%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

SELL
$159.82 - $182.1 $277,607 - $316,307
-1,737 Reduced 2.76%
61,196 $11.1 Million
Q4 2023

Jan 17, 2024

SELL
$137.6 - $154.97 $40,179 - $45,251
-292 Reduced 0.46%
62,933 $9.75 Million
Q3 2023

Oct 13, 2023

SELL
$133.59 - $154.65 $128,647 - $148,927
-963 Reduced 1.5%
63,225 $9.42 Million
Q2 2023

Jul 11, 2023

SELL
$132.51 - $164.9 $1.03 Million - $1.28 Million
-7,772 Reduced 10.8%
64,188 $8.65 Million
Q1 2023

Apr 17, 2023

SELL
$144.61 - $166.54 $349,522 - $402,527
-2,417 Reduced 3.25%
71,960 $11.5 Million
Q4 2022

Jan 13, 2023

BUY
$138.31 - $165.87 $132,224 - $158,571
956 Added 1.3%
74,377 $12 Million
Q3 2022

Oct 11, 2022

SELL
$134.21 - $153.93 $118,104 - $135,458
-880 Reduced 1.18%
73,421 $9.85 Million
Q2 2022

Jul 19, 2022

SELL
$137.62 - $174.96 $242,348 - $308,104
-1,761 Reduced 2.32%
74,301 $11.4 Million
Q1 2022

Apr 14, 2022

SELL
$131.98 - $163.75 $201,533 - $250,046
-1,527 Reduced 1.97%
76,062 $12.3 Million
Q4 2021

Jan 21, 2022

BUY
$107.43 - $135.93 $277,921 - $351,650
2,587 Added 3.45%
77,589 $10.5 Million
Q3 2021

Oct 13, 2021

BUY
$106.4 - $120.78 $480,183 - $545,080
4,513 Added 6.4%
75,002 $8.09 Million
Q2 2021

Jul 15, 2021

SELL
$105.21 - $117.21 $208,315 - $232,075
-1,980 Reduced 2.73%
70,489 $7.94 Million
Q1 2021

Apr 05, 2021

SELL
$102.3 - $112.62 $57,288 - $63,067
-560 Reduced 0.77%
72,469 $7.84 Million
Q4 2020

Jan 12, 2021

BUY
$80.49 - $108.67 $77,109 - $104,105
958 Added 1.33%
73,029 $7.83 Million
Q3 2020

Dec 03, 2020

BUY
$85.91 - $100.83 $619,325 - $726,883
7,209 Added 11.11%
72,071 $6.31 Million
Q2 2020

Jul 09, 2020

BUY
$73.37 - $98.18 $293,480 - $392,720
4,000 Added 6.57%
64,862 $6.37 Million
Q1 2020

Apr 13, 2020

BUY
$64.5 - $97.79 $259,290 - $393,115
4,020 Added 7.07%
60,862 $4.64 Million
Q4 2019

Jan 29, 2020

BUY
$72.13 - $90.25 $154,141 - $192,864
2,137 Added 3.91%
56,842 $5.03 Million
Q3 2019

Nov 04, 2019

SELL
$62.98 - $75.72 $179,744 - $216,104
-2,854 Reduced 4.96%
54,705 $4.14 Million
Q2 2019

Aug 01, 2019

SELL
$65.7 - $83.98 $165,301 - $211,293
-2,516 Reduced 4.19%
57,559 $4.19 Million
Q1 2019

Apr 29, 2019

SELL
$77.14 - $90.79 $202,261 - $238,051
-2,622 Reduced 4.18%
60,075 $4.84 Million
Q4 2018

Feb 07, 2019

SELL
$77.85 - $96.01 $705,009 - $869,466
-9,056 Reduced 12.62%
62,697 $5.78 Million
Q3 2018

Oct 23, 2018

BUY
$88.91 - $98.84 $194,535 - $216,261
2,188 Added 3.15%
71,753 $6.79 Million
Q2 2018

Jul 19, 2018

SELL
$89.78 - $106.23 $89,331 - $105,698
-995 Reduced 1.41%
69,565 $6.45 Million
Q1 2018

Apr 30, 2018

SELL
$92.01 - $123.21 $204,722 - $274,142
-2,225 Reduced 3.06%
70,560 $6.68 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $267,784 - $293,647
-2,990 Reduced 3.95%
72,785 $7.04 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $5.29 Million - $6.76 Million
75,775
75,775 $6.73 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Jacobs & CO Portfolio

Follow Jacobs & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs & CO with notifications on news.